My colleague Dr Sharma briefly touched on, I guess, the points of difference between the bill that's currently before the House this evening and the therapeutic products bill in what it seeks to achieve—which will be, I guess, more of a wholesome, more complete approach to the industry, or some form of regulation where it would look to address issues like the use of accreditation of labs. So not just using any laboratories up and down the country but making sure that there is a regulatory system in place for accreditation of the use and operation of those. So that's the first thing. The second, I think, we anticipate, would be around the frequency of testing—how often things would be tested—the procedures by which the testing would be undertaken, if there was some testing to take place. And then, of course, a third is, I guess, around that quality assurance—ensuring that those that are manufacturing products are doing so in an environment that is controlled in a quality sense.